Beatriz Cortez Ferreira

Beatriz Cortez Ferreira

Auto-generated profile, based on publicly available information

Beatriz Cortez Ferreira

Nephrology Department, Unidade Local de Saúde de Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Kidney360
Verified
Journal Article
Open access
JVJoão Venda
João Venda
BFBeatriz Ferreira
Beatriz Ferreira
AHAndreia Henriques
Andreia Henriques
PCPedro Castro
Pedro Castro
RLRita Leal
Rita Leal
RARui Alves
Rui Alves
An abstract is unavailable. This article is available as a PDF only.

6 March 2026 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
BFBeatriz Cortez Ferreira
Beatriz Cortez Ferreira
GSGabriela Matos Silva
Gabriela Matos Silva
JVJoão Venda
João Venda
NANuno Afonso
Nuno Afonso
RLRita Leal
Rita Leal
HSHelena Sá
Helena Sá
The complement system is a vital component of innate immunity, known for its role in pathogen defense. It has been increasingly recognized as a mediator of homeostatic clearance, tissue repair, and immune-metabolic crosstalk. In the kidney, unique anatomical and hemodynamic features predispose to aberrant complement activation, rendering glomerular structures particularly vulnerable. Complement dysregulation is implicated in a broad spectrum of kidney diseases – ranging from primary complement-driven disorders (atypical hemolytic uremic syndrome, C3 glomerulopathy, and emergent C4 glomerulopathy) to secondary complement disorders, with special emphasis on classical immune complex diseases, podocytopathies, and kidney transplantation. Within glomeruli, complement activation triggers non-lytic cellular activation (including calcium influx, kinase signaling, cytokine release, and cytoskeletal remodeling), inflammation, cytotoxic injury, and maladaptive remodeling via effectors such as C3a, C5a, and the membrane attack complex (C5b-9). Genetic and autoantibody–mediated defects in complement regulators amplify this risk. Recent advances in complement-targeted therapies—including inhibitors of C3, C5, factor B, and MASP-2—are entering glomerular disease trials, with early evidence of efficacy in proteinuria reduction and slowing of glomerular injury. Nevertheless, key challenges remain: balancing infection risk, defining appropriate durations, selecting responsive patient populations based on complement pathway profiling, and achieving cost-effectiveness. Looking ahead, integration of genetic, proteomic, and histopathologic biomarkers will be essential to implement a precision-medicine approach. Complement remains a frontier in glomerular disease research, bridging fundamental immunology to translational nephrology and offering new pathways to modify disease progression.

10 April 2025 in Gene & Protein in Disease
Verified
Journal Article
Open access
PDF file
JVJoão Venda
João Venda
BFBeatriz Ferreira
Beatriz Ferreira
AHAndreia Henriques
Andreia Henriques
RLRita Leal
Rita Leal
AGAna Galvão
Ana Galvão
RARui Alves
Rui Alves
Nearly a century has passed since Cecil A. Alport first described the triad of nephritis, hearing loss, and ocular abnormalities that would later be recognized as the second most common inherited nephropathy and a significant cause of end-stage kidney disease. Pathogenic variants in COL4A3, COL4A4, and COL4A5 genes lead to compromised synthesis, assembly, and/or function of α3, α4, and α5 chains of type IV collagen (COL4). This disruption leads to an abnormal trimerization of COL4 into a stable network, impairing the integrity and function of glomerular, cochlear, and ocular basement membranes. The gold standard for Alport syndrome diagnosis is molecular genetic testing, which provides a non-invasive and highly specific approach. In settings with limited access to genetic testing, kidney biopsy with electron microscopy remains essential, revealing characteristic glomerular basement membrane abnormalities. Despite significant advancements in understanding its genetic and molecular basis, Alport syndrome remains a relentlessly progressive disorder, often culminating in end-stage kidney disease during early adulthood. While no disease-specific therapy exists, early initiation of renin-angiotensin-aldosterone system blockade is the cornerstone of AS management, delaying disease progression. Emerging therapies, including sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists, are being investigated for their nephroprotective potential. In addition, recent breakthroughs in therapeutic research – including gene- and cell-based treatments – hold the potential to transform disease management. Genetic factors influence treatment response, reinforcing the need for personalized therapeutic approaches. In this review, we discuss the genetic background and phenotypic correlations of Alport syndrome, the pathophysiological mechanisms driving both renal and extrarenal manifestations, and explore diagnostic approaches and emerging strategies aimed at modifying the natural course of this disease.

7 July 2026 in Transplantation Proceedings
Verified
Journal Article
Open access
BFBeatriz Cortez Ferreira
Beatriz Cortez Ferreira
SVSofia Ventura
Sofia Ventura
CPClara Pardinhas
Clara Pardinhas
RLRita Leal
Rita Leal
LRLuís Rodrigues
Luís Rodrigues
AFArnaldo Figueiredo
Arnaldo Figueiredo
Kidney transplantation is the optimal renal replacement therapy, offering superior survival and quality of life compared with dialysis. Although outcomes after repeat transplantation may be inferior to those of first transplantation, retransplantation provides a survival benefit compared with remaining on dialysis. Living donor kidney transplantation (LDKT) offers advantages such as improved HLA matching and reduced cold ischemia time, potentially mitigating retransplantation-related risks. We performed a retrospective single-center study including all LDKT performed at ULS Coimbra between 2009-2020, with a mean follow-up of 9 years. Clinical and immunological donor-recipient variables were collected. Death-censored graft survival was assessed using Kaplan-Meier analysis and univariable Cox regression was used to explore predictors of graft loss. Acute rejection was defined according to Banff 2019 criteria. Seventy-six patients were included: 63 underwent a first LDKT and 13 a second LDKT. Baseline characteristics were similar regarding gender, dialysis vintage, HLA mismatches, and cold ischemia time. Second LDKT recipients were older (42 vs 33 years, p = 0.025), had higher historical panel reactive antibody levels, and more frequently received thymoglobulin induction (69.2% vs 16.7%, p < 0.001). Serum creatinine at 1 year was associated with graft loss (p = 0.007). Acute rejection was rare (4% vs 0%). Five- and 10-year death-censored graft survival was comparable between first and second LDKT (88.9% and 87.3% vs 100% and 92.3%, respectively). Second living donor kidney transplantation achieved excellent long-term graft survival comparable to first transplantation, supporting its safety and efficacy.